Eli Lilly and Company (LLY) Valuation — DCF & Advanced Analysis | MarketCI

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

LLY

Market Closed

Eli Lilly and Company

NYSEHealthcare Drug Manufacturers - General

50.00K employees

CEO: David A. Ricks

Founded: 1972

$1,185.71

+$0.00(+NaN%)

Market Cap

1.12T

Beta

0.51

52W Range

N/A

Dividend Yield

0.54%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Comprehensive Valuation

In-depth valuation analysis including DCF scenarios and peer comparisons.

AI Insight: Eli Lilly’s current price exceeds the high-confidence fair value estimate by 37%, signaling potential overvaluation amid a wide Monte Carlo volatility range and 84.4% downside risk below current price. Strong financial health contrasts with valuation metrics suggesting significant downside. Analyst targets and trading ranges partially justify the premium but introduce high uncertainty.

Enhanced Football Field Analysis

Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore LLY

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples